NCT00439751View on ClinicalTrials.gov

Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2015

Study Completion Date

June 30, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Goserelin Acetate

Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.

Trial Locations (11)

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

British Columbia Cancer Agency - Vancouver Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

L8V 1C3

Juravinski Cancer Centre, Hamilton

N6A 4L6

London Regional Cancer Program, London

K1H 1C4

Ottawa Hospital Regional Cancer Centre, Ottawa

M4N 3M5

Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto

H2L 4M1

CHUM - Hôpital Notre-Dame, Montreal

H2W 1S5

McGill Clinical Research Program, Montreal

G1R 2J6

CHUQ, L'Hotel-Dieu de Quebec, Québec

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Ontario Clinical Oncology Group (OCOG)

OTHER